Many trials were designed to explore cardiovascular safety or benefit using SGLT2i molecules, including empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin, which greatly differ in their characteristics, including the number of participants, study duration, the inclusion of patients with HF or renal disease, HF characterized by reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), and associated comorbidities or risk factors, clearly implying differences in the risk and rate of cardiovascular or renal events recorded during the investigations [2]
One of the most striking shifts is a move away from sheer quantity toward perceived quality
When your gut bacteria consume these fibers, they produce short-chain fatty acids like butyrate, which also trigger the release of GLP-1
Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (SURPASS) studies have shown that tirzepatide reduced HbA1c and fasting glucose levels more than the titrated insulin degludec, insulin glargine or 1 mg once a week semaglutide independently of the baseline levels of HbA1c
Log in to your Pharmacists Letter, Pharmacy Technicians Letter ,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses
Colten I joined Rejuvime a few months ago and couldnt be happier
